LA JOLLA, Calif.--(BUSINESS WIRE)--Arialys Therapeutics, a clinical-stage biotechnology company pioneering new precision medicines for autoimmune neuropsychiatric diseases, today announced the ...

MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD MIAMI, FLORIDA / ACCESS Newswire / September 16, 2025 / MIRA ...

A systematic review and meta-analysis of over 140 studies sheds light on which drug classes, including NMDA-receptor antagonists and VGSC blockers, can reduce secondary hyperalgesia.

Researchers from the Institute for Neurosciences (IN), a joint center of the Miguel Hernández University of Elche (UMH) and the Spanish National Research Council (CSIC), who are also part of the ...

SaveHealth reports on advancements in dementia medications, highlighting new treatments that modify disease progression and ...

Autism spectrum disorder (ASD) is widely known for its core features, which include difficulties in social communication and ...

Neurons generated from stem cells (from skin fibroblasts) of a patient with sporadic Alzheimer’s disease. Visualized with a specific green fluorescent marker. Nuclei are shown in blue. Researchers ...

In a recent study published in Nature, researchers developed the MK-801 bimodal drug that successfully cures obesity, hyperglycemia, and dyslipidemia in mouse models of metabolic illness by combining ...

This is a preview. Log in through your library . Abstract The unconventional N-methyl-D-aspartate (NMDA) receptor subunits GluN3A and GluN3B can, when associated with the other glycine-binding subunit ...

Cough-focused biotech Seyltx has secured the option to license a portfolio of eight GluN2B antagonists from NeurOp, including one candidate that has completed a phase 1 trial. The drugs are all ...